Please login to the form below
New accounts: February
The following table lists new pharmaceutical account wins notified to us by the winning agencies for the period November 2005 to January 2006 inclusive
The following table lists new pharmaceutical account wins notified to us by the winning agencies for the period November 2005 to January 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email nhobson@pmlive.com
|
|
|
|
|
|
Astellas |
Pan-European corporate profiling |
Corporate |
The Choice Group |
|
Boehringer Ingelheim/Lilly UK |
Cymbalta |
Neurology |
Virgo Health PR |
|
Cephalon |
Actiq |
Pain |
TVF Communications |
|
Novartis |
Aclasta |
CRM |
MRM Worldwide |
|
Novartis |
Prexige |
Osteoarthritic pain |
Clew Communications |
|
Novartis |
Transplantation portfolio |
Transplantation |
LeapFrog Medical |
|
Pfizer |
Diovan/Codiovan |
Hypertension |
TVF Communications |
|
Pfizer |
Injectable contraceptive |
Contraception |
Ruder Finn |
|
Roche |
Avastin |
Oncology |
Ketchum |
|
Solvay |
Omacor |
Cardiology |
LeapFrog Medical |
|
UCB Pharma |
Equasym XL |
ADHD |
TVF Communications |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
